Molecular Endocrinology, Vol 8, 1681-1690, Copyright © 1994 by Endocrine Society

ARTICLES

Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells

TM Molis, LL Spriggs and SM Hill
Department of Anatomy, Tulane University School of Medicine, New Orleans, Louisiana 70112.

Melatonin, the hormonal product of the pineal gland, has been shown to inhibit the development of mammary tumors in vivo and the proliferation of MCF-7 human breast cancer cells in vitro by mechanisms not yet identified. However, previous studies have demonstrated that melatonin significantly decreased estrogen-binding activity and the expression of immunoreactive estrogen receptor (ER) in MCF-7 breast cancer cells. To determine the mechanism(s) by which melatonin regulates ER expression in MCF-7 cells, the relationship between the level of steady state ER mRNA and the rate of ER gene transcription were examined in response to melatonin. Physiological concentrations of melatonin decreased steady state levels of ER mRNA expression in a dose- and time-specific manner. This decrease was not dependent upon the presence of estrogen since similar decreases in steady state ER mRNA levels were seen in MCF-7 cells cultured in both complete and estrogen-depleted media. The decreased expression of ER mRNA in response to melatonin appears to be directly related to the suppression of transcription of the ER gene. This regulation is independent of the synthesis of new proteins, as cycloheximide was unable to block the melatonin-induced decrease of steady-state ER mRNA levels. The down-regulation of ER by melatonin appears to not be mediated via a direct interaction with the ER and subsequent feedback on its own expression, since melatonin treatment did not alter the transcriptional regulatory ability of the fully activated wild type ER or a constitutively active hormone-binding domain-deleted ER variant. In addition, the stability of the ER transcript was unaffected by melatonin. Thus, it appears that the antiproliferative actions of this pineal indoleamine are mediated, at least in part, through the suppression of the transcription of the ER gene in MCF-7 human breast cancer cells.

This article has been cited by other articles:

				E. S. Schernhammer and S. E. Hankinson Urinary Melatonin Levels and Postmenopausal Breast Cancer Risk in the Nurses' Health Study Cohort Cancer Epidemiol. Biomarkers Prev., January 1, 2009; 18(1): 74 - 79. [Abstract] [Full Text] [PDF]

				V. Srinivasan, D W. Spence, S. R. Pandi-Perumal, I. Trakht, and D. P. Cardinali Therapeutic Actions of Melatonin in Cancer: Possible Mechanisms Integr Cancer Ther, September 1, 2008; 7(3): 189 - 203. [Abstract] [PDF]

				U. Ohnemus, M. Uenalan, J. Inzunza, J.-A. Gustafsson, and R. Paus The Hair Follicle as an Estrogen Target and Source Endocr. Rev., October 1, 2006; 27(6): 677 - 706. [Abstract] [Full Text] [PDF]

				V. Martin, F. Herrera, P. Carrera-Gonzalez, G. Garcia-Santos, I. Antolin, J. Rodriguez-Blanco, and C. Rodriguez Intracellular Signaling Pathways Involved in the Cell Growth Inhibition of Glioma Cells by Melatonin Cancer Res., January 15, 2006; 66(2): 1081 - 1088. [Abstract] [Full Text] [PDF]

				B. del Rio, J. M. G. Pedrero, C. Martinez-Campa, P. Zuazua, P. S. Lazo, and S. Ramos Melatonin, an Endogenous-specific Inhibitor of Estrogen Receptor {alpha} via Calmodulin J. Biol. Chem., September 10, 2004; 279(37): 38294 - 38302. [Abstract] [Full Text] [PDF]

				R. C. Travis, D. S. Allen, I. S. Fentiman, and T. J. Key Melatonin and Breast Cancer: A Prospective Study J Natl Cancer Inst, March 17, 2004; 96(6): 475 - 482. [Abstract] [Full Text] [PDF]

				G. Izzo, M. d'Istria, I. Serino, and S. Minucci Inhibition of the increased 17{beta}-estradiol-induced mast cell number by melatonin in the testis of the frog Rana esculenta, in vivo and in vitro J. Exp. Biol., February 1, 2004; 207(3): 437 - 441. [Abstract] [Full Text] [PDF]

				M. Fedrowitz, K. Kamino, and W. Loscher Significant Differences in the Effects of Magnetic Field Exposure on 7,12-Dimethylbenz(a)anthracene-Induced Mammary Carcinogenesis in Two Substrains of Sprague-Dawley Rats Cancer Res., January 1, 2004; 64(1): 243 - 251. [Abstract] [Full Text] [PDF]

				M. Fedrowitz, J. Westermann, and W. Loscher Magnetic Field Exposure Increases Cell Proliferation but Does Not Affect Melatonin Levels in the Mammary Gland of Female Sprague Dawley Rats Cancer Res., March 1, 2002; 62(5): 1356 - 1363. [Abstract] [Full Text] [PDF]

				D. Roy and D. D. Belsham Melatonin Receptor Activation Regulates GnRH Gene Expression and Secretion in GT1-7 GnRH Neurons. SIGNAL TRANSDUCTION MECHANISMS J. Biol. Chem., January 4, 2002; 277(1): 251 - 258. [Abstract] [Full Text]

				D. Roy, N. L. Angelini, H. Fujieda, G. M. Brown, and D. D. Belsham Cyclical Regulation of GnRH Gene Expression in GT1-7 GnRH-Secreting Neurons by Melatonin Endocrinology, November 1, 2001; 142(11): 4711 - 4720. [Abstract] [Full Text] [PDF]

				D. E. Blask, L. A. Sauer, R. T. Dauchy, E. W. Holowachuk, M. S. Ruhoff, and H. S. Kopff Melatonin Inhibition of Cancer Growth in Vivo Involves Suppression of Tumor Fatty Acid Metabolism via Melatonin Receptor-mediated Signal Transduction Events Cancer Res., September 1, 1999; 59(18): 4693 - 4701. [Abstract] [Full Text] [PDF]

				A. GARCÍA RATO, J. GARCÍA PEDRERO, M. A. MARTÍNEZ, B. DEL RIO, P. S. LAZO, and S. RAMOS Melatonin blocks the activation of estrogen receptor for DNA binding FASEB J, May 1, 1999; 13(8): 857 - 868. [Abstract] [Full Text]

				S. Doolen, D. N. Krause, and S. P. Duckles Estradiol modulates vascular response to melatonin in rat caudal artery Am J Physiol Heart Circ Physiol, April 1, 1999; 276(4): H1281 - H1288. [Abstract] [Full Text] [PDF]

				D. R. Weaver Reproductive Safety of Melatonin: A "Wonder Drug" to Wonder About J Biol Rhythms, December 1, 1997; 12(6): 682 - 689. [Abstract] [PDF]

				A. Brzezinski Melatonin in Humans N. Engl. J. Med., January 16, 1997; 336(3): 186 - 195. [Full Text] [PDF]